QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 13 February 2024Portfolio NewsTransposon Announces Final Results from a Phase 2 Study of its LINE-1 Reverse Transcriptase Inhibitor TPN-101 for the Treatment of Progressive Supranuclear Palsy and Interim Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyo
- 13 February 2024Portfolio NewsSudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M
- 13 February 2024Portfolio NewsEyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restoret at Macula Society Annual Meeting
- 13 February 2024Portfolio NewsBioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics
- 7 February 2024SV NewsKate Bingham Participates in The Times' Health Commission Report Summit
- 19 January 2024Portfolio NewsPrilenia Announces Clinical Data in Support of its Plans to Initiate Global Phase 3 Study in ALS
- 11 January 2024SV NewsSV investment has resulted in the approval of 24 novel therapeutics
- 8 January 2024SV NewsSV is hiring: Executive Assistant
- 8 January 2024SV NewsSV is hiring: Analyst / Associate - Biotech team
- 4 January 2024Portfolio NewsSitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases
- 4 January 2024Portfolio NewsBoehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC)
- 4 January 2024SV NewsSV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner